| Company Name: |
LGM Pharma |
| Tel: |
1-(800)-881-8210 |
| Email: |
inquiries@lgmpharma.com |
|
| | SERGLIFLOZIN Basic information |
| Product Name: | SERGLIFLOZIN | | Synonyms: | SERGLIFLOZIN;2-[(4-Methoxyphenyl)methyl]phenyl-beta-D-glucopyranoside-6-(ethyl carbonate);QLXKHBNJTPICNF-QMCAAQAGSA-N;2-(4-Methoxybenzyl)phenyl6-O-(ethoxycarbonyl)-beta-D-glucopyranoside;ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-[(4-methoxyphenyl)methyl]phenoxy]oxan-2-yl]methyl carbonate;β-D-Glucopyranoside,2-[(4-methoxyphenyl)methyl]phenyl,6-(ethyl carbonate);GW869682;GW-869682 | | CAS: | 408504-26-7 | | MF: | C23H28O9 | | MW: | 448.46 | | EINECS: | | | Product Categories: | | | Mol File: | 408504-26-7.mol |  |
| | SERGLIFLOZIN Chemical Properties |
| Boiling point | 611.5±55.0 °C(Predicted) | | density | 1.312 | | pka | 12.74±0.70(Predicted) | | form | Solid | | color | White to off-white |
| | SERGLIFLOZIN Usage And Synthesis |
| Uses | Treatment of type 2 diabetes. | | Definition | ChEBI: Sergliflozin etabonate is a glycoside. | | in vivo | Sergliflozin etabonate (1, 3, 10, 30 mg/kg; oral; once) significantly reduces non-fasting blood glucose levels in KK-Ay mice in a dose-dependent manner[1].
Sergliflozin etabonate (1.7, 8.4, 45.7 mg/kg in the 0.001, 0.005, and 0.025% sergliflozin etabonate; fed; daily for 9 weeks) reduces non-fasting blood glucose level and decreases triglyceride content in the liver in a dose-dependent manner in KK-Ay mice[1]. | Animal Model: | 14 weeks, Female KK-Ay mice[1] | | Dosage: | 1, 3, 10, 30 mg/kg | | Administration: | Oral; once | | Result: | Significantly reduced non-fasting blood glucose level with the reduction in blood glucose level at 2 h post dosing in the 1 mg/kg group, 3 mg/kg group, 10 mg/kg group, and 30 mg/kg group was 12, 15, 28, and 39%, respectively. |
| Animal Model: | 4 weeks, Female KK-Ay mice[1] | | Dosage: | 1.7, 8.4, 45.7 mg/kg in the 0.001, 0.005, and 0.025% sergliflozin etabonate | | Administration: | Fed, daily for 9 weeks | | Result: | Reduced non-fasting blood glucose level and decreased triglyceride content in the liver in a dose-dependent manner in diabetic control KK-Ay mice. |
| | IC 50 | SGLT2 |
| | SERGLIFLOZIN Preparation Products And Raw materials |
|